Donanemab 257 patient phase 2 results with 25% dropout and with their primary endoint iARDS p value 0.04 and secondaries trending in right direction but all with non stat sig scores in ADAS COG, CDR SB, iADL and MMSE, the ARIA safety issues, extra unexplained brain volume loss, no intriguing sub group and no long term data at the time was valued at $22 billion going by implied market moves, but you think Blarcamesine 2b/3 currently worth $350 million?
Market Data 
Markets 
AI
